features: Biomarkers

Amyloid in Alzheimer’s disease: toxic accumulation or loss of normal function?

New data published in the Journal of Alzheimer’s disease suggest that the loss of soluble Aβ42 predicts cognitive decline better…

Breakthrough in Alzheimer’s disease diagnosis: FDA authorizes diagnostic test for β-amyloid plaques

The U.S. Food and Drug Administration (FDA) has authorized the marketing of the Fujirebio’s Lumipulse G β-Amyloid Ratio (1-42/1-40) in…

Highlights from ARUK 2022

The Alzheimer’s Research UK Conference was held in Brighton, UK, on 1-2 March 2022. Leading experts discussed the key topics…